Comparing Disitamab Vedotin Plus Pyrotinib With Standard THP Treatment for HER2-positive Advanced Breast Cancer in Adults
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2024-02-26
312
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a new combination treatment using disitamab vedotin and pyrotinib compared to the current standard first-line therapy of paclitaxel combined with trastuzumab and pertuzumab for women newly diagnosed with recurrent or metastatic HER2-positive advanced breast cancer. This phase III randomized, double-blind trial also explores how biomarkers might influence treatment outcomes and safety.
Participants in the experimental group receive disitamab vedotin intravenously every 14 days at 2 mgkg combined with daily oral pyrotinib in 28-day cycles for 6 to 8 cycles, followed by maintenance treatment with trastuzumab and pyrotinib. The control group receives a taxane drug such as docetaxel or paclitaxel with trastuzumab and pertuzumab every 21 days for 6 to 8 cycles, followed by maintenance therapy with trastuzumab and pertuzumab. Treatment dosing aligns with national guidelines for breast cancer therapy.
During the study, participants will have regular assessments including tumor measurements, organ function tests, and quality of life evaluations. Researchers will monitor progression-free survival over about 30 months, along with overall survival, disease control rates, response rates, clinical benefits, adverse events, and biomarker effects. Safety monitoring continues through treatment completion, with the total study duration extending to 8 years for some outcomes.
CONDITIONS
Brief Title
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead Sponsor
Who Can Participate
Age: 18Years - 75Years
FEMALE
Eligibility Criteria
You may qualify if you...
Female patients aged 18 to 75 years with metastatic breast cancer confirmed by pathology or imaging
Pathologically confirmed HER2 positive status (IHC 3+ or IHC 2+ with FISH amplification)
No prior chemotherapy for metastatic breast cancer
At least one measurable lesion according to RECIST 1.1 criteria
ECOG performance status score of 0 to 2 and expected survival of at least 3 months
Prior treatment-related toxicities resolved to CTCAE v5.0 grade 1 or lower (except alopecia or non-safety risks)
Adequate blood counts: WBC ≥ 3.0 x 10^9/L, ANC ≥ 1.5 x 10^9/L, Platelets ≥ 70 x 10^9/L
Normal liver, kidney, and cardiac function within defined lab limits
Left ventricular ejection fraction ≥ 55% and QTcF ≤ 470ms
Clear hormone receptor status
Negative pregnancy test and agreement to effective non-hormonal contraception during treatment and for 6 months after
Ability to understand the study and voluntarily provide informed consent
You will not qualify if you...
HER2 negative pathology (IHC 2+ with FISH negative or IHC 1+)
Known allergy to study drug ingredients
Pregnancy or breastfeeding, positive pregnancy test at baseline, or unwillingness to use contraception
Any serious medical condition or pre-existing disease that may interfere with study participation or safety, such as uncontrolled heart disease, high blood pressure, active infections, or active hepatitis B infection
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 6 to 8 cycles of combination therapy followed by maintenance therapy; each cycle is 21 or 28 days depending on treatment arm
Participants receive assigned study drugs according to their treatment arm: either disitamab vedotin with pyrotinib followed by maintenance with trastuzumab and pyrotinib, or taxane drug combined with trastuzumab and pertuzumab followed by maintenance with trastuzumab and pertuzumab.
Regular visits every 14 or 21 days during combination therapy and maintenance
Follow-up
Duration - Up to 28 days following treatment completion
Participants are monitored for adverse events and long-term outcomes after treatment completion.
Approximately 1 to 2 visits after treatment ends
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase II Study of Tucatinib, Capecitabine, and Intrathecal Trastuzumab for HER2-Positive Breast Cancer Patients with Leptomeningeal Metastases
Study of Dalpiciclib Combined With Anti-HER2 and Endocrine Therapy as First-Line Maintenance for Women With Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Comparing Disitamab Vedotin Plus Pyrotinib With Standard THP Treatment for HER2-positive Advanced Breast Cancer in Adults
Open-label Study Evaluating HER3-DXd Alone and With Other Agents in Advanced Breast Cancer After T-DXd Progression
Phase 1a1b Open-Label Study Assessing BBO-10203 Alone and with Other Cancer Drugs in Advanced Solid Tumors
Study of Paclitaxel Cationic Liposome Delivered by Liver Artery with Systemic Therapy as First Treatment for Colorectal Cancer Spread to Liver
PRE-ISPY Phase III Platform Trial of Multiple Drug Regimens for Advanced and Metastatic Solid Tumors
QuantifyHER Study to Measure HER2 Levels Using Immunofluorescence and RT-qPCR in Adults with HER2-low Metastatic Breast Cancer Receiving T-DXd
Feasibility Study of CNS MRI Surveillance Versus No Routine Surveillance in Adults with HER2-Positive Metastatic Breast Cancer
Feasibility Study of Precision Medicine to Guide Oxaliplatin or Irinotecan Chemotherapy for Adults with Metastatic Colorectal Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
Rositsa G Koleva-Kolarova, Monika P Oktora, Annelies L Robijn...